]>
IRCT20101020004976N6 IRCT 2020-07-18 Mashhad University of Medical Sciences The effect of Lactocare® synbiotic on the prevention of COVID-19 infection in the staff of emergency department Investigation of the effect of Lactocare® synbiotic on the prevention of COVID-19 infection in the staff of emergency department 2020-05-14 anticipated 80 Complete https://irct.ir/trial/49670 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Simple randomization with table of random numbers available at ''www.randomization.com'' website will be used. Numbers will be placed in sealed envelopes and each envelope is assigned to one participant placing them in one of the two groups, Blinding description: In this study, participants are not aware of the type of treatment and the intervention. Also, outcome assessors are unaware of the grouping. Patients in the control group receive placebo drug. 3 COVID-19 disease. Intervention 1: Intervention group: In this group, patients will receive a Lactocare® synbiotice capsule daily for a month. Intervention 2: Control group: Patients in this group will receive a capsule as placebo (with the same shape, smell, design and color) containing no probiotic daily for one month. Yes - There is a plan to make this available What will be shared: All data can be shared after patients are made unidentifiable. When: Data can be accessible 6 months after results are published. To whom: Data will be available for researchers in universities and other scientific institutes. Conditions: Carrying out analysis on data is permitted. Where to obtain: Data can be accessible through an email to the corresponding author. How to obtain: After sending a request email to the corresponding author, data will be sent in 1 month. Comments: After sending a request email to the corresponding author, data will be sent in 1 month.
public Hamid Ahanchian
Ghaem hospital, Ahmad Abad blvd
Mashhad Iran (Islamic Republic of) 9176999311 +98 51 3801 2469 ahanchianh@mums.ac.ir Mashhad University of Medical Sciences scientific Hamid Ahanchian
Ghaem hospital, Ahmad Abad blvd
Mashhad Iran (Islamic Republic of) 9176999311 +98 51 3801 2469 ahanchianh@mums.ac.ir Mashhad University of Medical Sciences Iran (Islamic Republic of) Being a member of the personnel (including physicians and nurses) of the emergency department of Imam Reza hospital Active presence in the wards where patients with COVID-19 are hospitalized 18 years no limit Both History of clinical or laboratory diagnosis with COVID-19 U07.1 Coronavirus infection, unspecified Treatment - Drugs Placebo Intervention group: In this group, patients will receive a Lactocare® synbiotice capsule daily for a month. Control group: Patients in this group will receive a capsule as placebo (with the same shape, smell, design and color) containing no probiotic daily for one month. Fever. Timepoint: Before during and after treatment. Method of measurement: Thermometer. Findings of CT scan and CXR. Timepoint: After treatment. Method of measurement: CT scan and CXR machines. Number of lymphocytes. Timepoint: Before and after treatment. Method of measurement: Biochemical tests. WBC. Timepoint: Before and after treatment. Method of measurement: Biochemical tests. Infection by COVID-19. Timepoint: Before treatment, during treatment if symptoms appear and at the end of treatment. Method of measurement: PCR and antibody tests. Cough and sore throat. Timepoint: Before, during and after treatment. Method of measurement: Clinical observations. Nausea, vomiting and diarrhea. Timepoint: Before, during and after treatment. Method of measurement: Clinical observations. Mashhad University of Medical Sciences Approved 2020-05-09 Ethic committe of Mashhad university of Medical Sciences Ghoreyshi Building, Daneshgah street, Mashhad Iran Mashhad Razavi Khorasan Iran (Islamic Republic of)